{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T08:08:19Z","timestamp":1753862899426,"version":"3.41.2"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Case Reports"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nivolumab belongs to immune checkpoint inhibitors (ICIs). ICIs\u2010induced kidney injury is rare and acute interstitial nephritis (AIN) is the majority. A 58\u2010year\u2010old woman had gastric cancer treated with nivolumab. Her serum creatinine (Cr) increased to 5.94\u2009mg\/dL post 2 cycles of nivolumab and co\u2010administered with acemetacin. A kidney biopsy showed acute tubular injury (ATI). Nivolumab rechallenge was done and Cr worsened again. The lymphocyte transformation test (LTT) indicated a strong positive for nivolumab. Although rare, ATI due to ICIs could not be ruled out, and LTT is a tool to identify the culprit.<\/jats:p>","DOI":"10.1002\/ccr3.6991","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T04:36:57Z","timestamp":1678250217000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nivolumab\u2010induced acute tubular <scp>injury: A<\/scp> case report"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2204-2087","authenticated-orcid":false,"given":"Hui\u2010Hsin","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy Chang Gung Memorial Hospital, Taoyuan  Taoyuan City Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia\u2010Wen","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Chang Gung Memorial Hospital, Taoyuan  Taoyuan City Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai\u2010Di","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology Chang Gung Memorial Hospital, Linkou  Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"issue":"1","key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single\u2010center experience","volume":"7","author":"Omar M","year":"2019","journal-title":"J Immunother Cancer"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2021.08.008"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.008"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.02.057"},{"issue":"1","key":"e_1_2_11_6_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Mu\u00f1oz AM","year":"2020","journal-title":"J Immunother Cancer"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy100"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.04.026"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.13064"},{"key":"e_1_2_11_10_1","first-page":"3614980","article-title":"Acute interstitial nephritis in a patient with non\u2010small cell lung cancer under immunotherapy with nivolumab","volume":"15","author":"Georgianos PI","year":"2019","journal-title":"Case Rep Nephrol"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.05.024"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1848"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000455014"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01173"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.06.028"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220921543"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2016.11.004"},{"issue":"2","key":"e_1_2_11_18_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD\u20101\/PD\u2010L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini A","year":"2020","journal-title":"J Immunother Cancer"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019070676"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000520798"},{"key":"e_1_2_11_21_1","unstructured":"National Cancer Institute.Common terminology criteria for adverse events (CTCAE) version 5.0;2017.https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronicapplications\/docs\/CTCAEv5QuickReference8.5x11.pdf"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000852019"},{"issue":"5","key":"e_1_2_11_24_1","first-page":"887","article-title":"Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors","volume":"37","author":"Carro CG","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"e_1_2_11_25_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz\u2010Munoz A","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.6991","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ccr3.6991","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.6991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:38:44Z","timestamp":1750480724000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccr3.6991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/ccr3.6991"],"URL":"https:\/\/doi.org\/10.1002\/ccr3.6991","archive":["Portico"],"relation":{},"ISSN":["2050-0904","2050-0904"],"issn-type":[{"type":"print","value":"2050-0904"},{"type":"electronic","value":"2050-0904"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"2022-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e6991"}}